Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

260
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
260
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

205
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
205
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

218
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
218
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

221
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
221
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

178
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
178
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

166
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
166

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same author

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same author

Predictive Biomarker Graphical Approach (PRIME) for Precision Medicine.

Pharmaceutical statistics·2026
Same author

Tutorial on Firth's Logistic Regression Models for Biomarkers in Preclinical Space.

Pharmaceutical statistics·2024
Same author

Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program.

BMJ open diabetes research & care·2021
Same author

FERTILIZATION-INDEPENDENT SEED-Polycomb Repressive Complex 2 Plays a Dual Role in Regulating Type I MADS-Box Genes in Early Endosperm Development.

Plant physiology·2018

相关实验视频

Updated: Jan 14, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

基于实用性的剂量优化方法用于多剂量随机试验设计,考虑多个终点.

Gina D'Angelo1, Guannan Chen1,2, Di Ran1

  • 1Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.

Pharmaceutical statistics
|October 20, 2025
PubMed
概括

新的方法U-MET-m和CUI-MET通过优化剂量选择来增强瘤学临床试验. 这些方法有效地使用多个终点和剂量确定最佳生物剂量 (OBD).

关键词:
这就是CUI-MET.在U-MET-m.剂量优化剂量优化剂量随机化剂量随机化最优的生物剂量.公用事业公用事业公司

更多相关视频

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.8K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

相关实验视频

Last Updated: Jan 14, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.8K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

科学领域:

  • 临床试验 临床试验
  • 制药指标 (Pharmacometrics) 是一个指标.
  • 生物统计学 生物统计学

背景情况:

  • 在瘤学临床试验中,剂量优化对于确定最佳生物剂量 (OBD) 至关重要.
  • 结合安全性,有效性和生物标志物数据的早期试验可以促进OBD调查.
  • 现有的基于实用性得分的方法需要扩展,以有效处理多个终点和剂量.

研究的目的:

  • 扩展基于实用性得分的方法 (U-MET),以适应临床试验设计中的多个终点和剂量.
  • 引入U-MET-m用于多个终点 (≤3) 的联合会计,以及CUI-MET用于边际会计>3个终点.
  • 为U-MET-m提供重量选择指南,并证明U-MET-m和CUI-MET之间的关系.

主要方法:

  • 开发了U-MET-m (用于多剂量随机试验设计的基于实用性的剂量优化) 对≤3个终点,使用实用性得分来考虑联合终点.
  • 为>3个终点开发了CUI-MET (临床效用指数剂量优化方法),使用实用指数考虑边际终点.
  • 在假设框架内使用贝叶斯推理来比较公用事业指标并识别OBD,利用模拟研究和示例.

主要成果:

  • 无论是U-MET-m还是CUI-MET,都表现出了为选择最佳生物剂量 (OBD) 提供令人满意的操作特性.
  • 与实证设计相比,模拟研究和实例证实了拟议方法的有效性.
  • 在U-MET-m和CUI-MET之间建立了明确的关系,有助于U-MET-m的重量选择.

结论:

  • 推U-MET-m用于与≤3个终点进行剂量比较,而CUI-MET在选择OBD时推用于>3个终点.
  • 这些新的方法为瘤学临床试验中的剂量优化提供了强大的框架.
  • 这些发现支持更广泛地采用基于实用性的方法,以有效地设计临床试验和选择剂量.